Trial site
Medical center "Artmed" LTD
Plovdiv, 4002, BulgariaEU-13 widening countryNot linked to an institution yet
- 16running trials
- 11closed trials
The trials here
What the 27 trials at this site are about, from their registry records.
- Phase
- Phase 319 trials
- Phase 27 trials
- Phase 2/31 trial
- Status
- Completed11 trials
- Active, not recruiting9 trials
- Recruiting4 trials
- Not yet recruiting3 trials
- Lead sponsor
- MoonLake Immunotherapeutics AG3 trials
- argenx2 trials
- Pfizer2 trials
- Takeda2 trials
- AbbVie1 trial
- and 17 more
Running trials
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· Phase 3· Takeda· Source
Not yet recruiting
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)
2025-524005-32-00· Phase 2· Elevara Medicines Limited· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· Phase 3· Takeda· Source
Recruiting
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT06698796· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
2023-504022-19-01· Phase 3· AstraZeneca AB· Source
Enrolling by invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441· Phase 3· argenx· Source
Active, not recruiting
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643· Phase 3· AbbVie· Source
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786· Phase 3· Pfizer· Source
Recruiting
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
2022-500699-76-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Active, not recruiting
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500· Phase 3· Viatris Innovation GmbH· Source
Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
NCT05352919· Phase 3· Biogen· Source
Active, not recruiting
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202· Phase 3· Bristol-Myers Squibb· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)
NCT06684847· Phase 3· Argenx· Source
Completed
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
2024-514981-37-00· Phase 2· Synact Pharma ApS· Source
Completed
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
NCT06312020· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source
Completed
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228· Phase 3· UCB Biopharma SRL· Source
Completed
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis
2023-503790-37-00· Phase 3· Curateq Biologics Private Limited· Source
Completed
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
NCT05856448· Phase 2· Lakefront Biotherapeutics NV· Source
Completed
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
NCT05437263· Phase 3· Priovant Therapeutics, Inc.· Source
Completed
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
NCT05523167· Phase 2/3· argenx· Source
Completed
Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee
NCT05377489· Phase 3· Grünenthal GmbH· Source
Completed
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
NCT05162586· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Completed
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
NCT05198310· Phase 2· Kiniksa Pharmaceuticals, Ltd.· Source
Report an error